Cohen M B, Snow J S, Grasso V, Lehnert L, Goldner B G, Jadonath R L, Cohen T J
Department of Medicine, North Shore University Hospital-Cornell University Medical College, Manhasset, NY 11030, USA.
Am Heart J. 1995 Oct;130(4):786-90. doi: 10.1016/0002-8703(95)90078-0.
The purpose of this study was to evaluate the efficacy, safety, and tolerance of pindolol as initial therapy for vasovagal syncope. Head-up tilt table testing (HUT) was performed on 192 patients for syncope or near-syncope of unknown cause. Forty-four (23%) patients had a positive HUT for vasovagal syncope, and 28 (64%) received oral pindolol as initial therapy. Three patients were lost to follow-up; of the remaining 25 patients (mean age 60 +/- 22 years), 15 were women, 14 had syncope, and 11 had near-syncope. At 14 +/- 6 months' follow-up, 16 (64%) patients were without recurrence or side effects from pindolol. Of the 9 patients who stopped taking pindolol, 3 were switched to another regimen for recurrent symptoms, 2 stopped because of side effects, and 4 did not comply with the regimen. In conclusion, pindolol appears to be safe and effective as initial treatment for vasovagal syncope.
本研究的目的是评估吲哚洛尔作为血管迷走性晕厥初始治疗的疗效、安全性和耐受性。对192例不明原因晕厥或接近晕厥的患者进行了直立倾斜试验（HUT）。44例（23%）患者HUT结果为血管迷走性晕厥阳性，其中28例（64%）接受口服吲哚洛尔作为初始治疗。3例患者失访；其余25例患者（平均年龄60±22岁）中，15例为女性，14例有晕厥，11例有接近晕厥。在14±6个月的随访中，16例（64%）患者未出现吲哚洛尔引起的复发或副作用。在9例停止服用吲哚洛尔的患者中，3例因症状复发改用另一种治疗方案，2例因副作用停药，4例未遵医嘱治疗。总之，吲哚洛尔作为血管迷走性晕厥的初始治疗似乎是安全有效的。
